Literature DB >> 28298291

Plasmablast Response to Primary Rhesus Cytomegalovirus (CMV) Infection in a Monkey Model of Congenital CMV Transmission.

Qihua Fan1, Cody S Nelson1, Kristy M Bialas1, Flavia Chiuppesi2, Joshua Amos1, Thaddeus C Gurley1, Dawn Jones Marshall1, Joshua Eudailey1, Holly Heimsath1, Jonathon Himes1, Ashlesha Deshpande3, Mark R Walter3, Felix Wussow2, Don J Diamond2, Peter A Barry4, M Anthony Moody1, Amitinder Kaur5, Sallie R Permar6.   

Abstract

Human cytomegalovirus (HCMV) is the most common congenital infection worldwide and the leading infectious cause of neurologic deficits and hearing loss in newborns. Development of a maternal HCMV vaccine to prevent vertical virus transmission is a high priority, yet protective maternal immune responses following acute infection are poorly understood. To characterize the maternal humoral immune response to primary CMV infection, we investigated the plasmablast and early antibody repertoire using a nonhuman primate model with two acutely rhesus CMV (RhCMV)-infected animals-a CD4+ T cell-depleted dam that experienced fetal loss shortly after vertical RhCMV transmission and an immunocompetent dam that did not transmit RhCMV to her infant. Compared to the CD4+ T cell-depleted dam that experienced fetal loss, the immunocompetent, nontransmitting dam had a more rapid and robust plasmablast response that produced a high proportion of RhCMV-reactive antibodies, including the first identified monoclonal antibody specific for soluble and membrane-associated RhCMV envelope glycoprotein B (gB). Additionally, we noted that plasmablast RhCMV-specific antibodies had variable gene usage and maturation similar to those observed in a monkey chronically coinfected with simian immunodeficiency virus (SIV) and RhCMV. This study reveals characteristics of the early maternal RhCMV-specific humoral immune responses to primary RhCMV infection in rhesus monkeys and may contribute to a future understanding of what antibody responses should be targeted by a vaccine to eliminate congenital HCMV transmission. Furthermore, the identification of an RhCMV gB-specific monoclonal antibody underscores the possibility of modeling future HCMV vaccine strategies in this nonhuman primate model.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  congenital cytomegalovirus; nonhuman primates; vaccine

Mesh:

Year:  2017        PMID: 28298291      PMCID: PMC5424243          DOI: 10.1128/CVI.00510-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  47 in total

Review 1.  Cytomegalovirus vaccines.

Authors:  Michael A McVoy
Journal:  Clin Infect Dis       Date:  2013-12       Impact factor: 9.079

2.  Soluble Human Cytomegalovirus gH/gL/pUL128-131 Pentameric Complex, but Not gH/gL, Inhibits Viral Entry to Epithelial Cells and Presents Dominant Native Neutralizing Epitopes.

Authors:  John W Loughney; Richard R Rustandi; Dai Wang; Matthew C Troutman; Lawrence W Dick; Guanghua Li; Zhong Liu; Fengsheng Li; Daniel C Freed; Colleen E Price; Van M Hoang; Timothy D Culp; Pete A DePhillips; Tong-Ming Fu; Sha Ha
Journal:  J Biol Chem       Date:  2015-05-06       Impact factor: 5.157

3.  Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.

Authors:  Eduardo L V Silveira; Sudhir P Kasturi; Yevgeniy Kovalenkov; Ata Ur Rasheed; Patryce Yeiser; Zarpheen S Jinnah; Traci H Legere; Bali Pulendran; Francois Villinger; Jens Wrammert
Journal:  J Immunol Methods       Date:  2014-11-08       Impact factor: 2.303

4.  Cytomegalovirus vaccines and methods of production (WO20009049138): the emerging recognition of the importance of virus neutralization at the epithelial/endothelial interface.

Authors:  Mark R Schleiss
Journal:  Expert Opin Ther Pat       Date:  2010-04       Impact factor: 6.674

5.  Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity.

Authors:  S B Boppana; L B Rivera; K B Fowler; M Mach; W J Britt
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

6.  Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection.

Authors:  S B Boppana; W J Britt
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

7.  IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism.

Authors:  Dimitra Zotos; Jonathan M Coquet; Yang Zhang; Amanda Light; Kathy D'Costa; Axel Kallies; Lynn M Corcoran; Dale I Godfrey; Kai-Michael Toellner; Mark J Smyth; Stephen L Nutt; David M Tarlinton
Journal:  J Exp Med       Date:  2010-02-08       Impact factor: 14.307

8.  Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.

Authors:  Alexandre Harari; G Paolo Rizzardi; Kim Ellefsen; Donatella Ciuffreda; Patrick Champagne; Pierre-Alexandre Bart; Daniel Kaufmann; Amalio Telenti; Roland Sahli; Giuseppe Tambussi; Laurent Kaiser; Adriano Lazzarin; Luc Perrin; Giuseppe Pantaleo
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

9.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

10.  Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population.

Authors:  Marisa M Mussi-Pinhata; Aparecida Y Yamamoto; Rosângela M Moura Brito; Myriam de Lima Isaac; Patricia F de Carvalho e Oliveira; Suresh Boppana; William J Britt
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

View more
  8 in total

1.  A comparison of unamplified and massively multiplexed PCR amplification for murine antibody repertoire sequencing.

Authors:  Trisha A Rettig; Michael J Pecaut; Stephen K Chapes
Journal:  FASEB Bioadv       Date:  2018-08-30

2.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

Review 3.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

4.  Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.

Authors:  Bonnie Phillips; Genevieve G Fouda; Josh Eudailey; Justin Pollara; Alan D Curtis; Erika Kunz; Maria Dennis; Xiaoying Shen; Camden Bay; Michael Hudgens; David Pickup; S Munir Alam; Amir Ardeshir; Pamela A Kozlowski; Koen K A Van Rompay; Guido Ferrari; M Anthony Moody; Sallie Permar; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

5.  A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease.

Authors:  Anne H Rowley; Susan C Baker; David Arrollo; Leah J Gruen; Tetyana Bodnar; Nancy Innocentini; Matthew Hackbart; Yazmin E Cruz-Pulido; Kristine M Wylie; Kwang-Youn A Kim; Stanford T Shulman
Journal:  J Infect Dis       Date:  2020-06-16       Impact factor: 5.226

Review 6.  Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections.

Authors:  Hannah L Itell; Amitinder Kaur; Jesse D Deere; Peter A Barry; Sallie R Permar
Journal:  Curr Opin Virol       Date:  2017-09-06       Impact factor: 7.090

7.  A comparison of unamplified and massively multiplexed PCR amplification for murine antibody repertoire sequencing.

Authors:  Trisha A Rettig; Michael J Pecaut; Stephen K Chapes
Journal:  FASEB Bioadv       Date:  2018-10-25

Review 8.  Vaccines for Perinatal and Congenital Infections-How Close Are We?

Authors:  Tulika Singh; Claire E Otero; Katherine Li; Sarah M Valencia; Ashley N Nelson; Sallie R Permar
Journal:  Front Pediatr       Date:  2020-12-15       Impact factor: 3.418

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.